dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidineMonitor Closely (1)dexmedetomidine and buprenorphine both increase sedation. Use Caution/Monitor.dextroamphetamineMinor (1)dextroamphetamine increases effects of buprenorphine by unspecified interaction mechanism. Minor/Significance Unknown.dextromoramideMonitor Closely (1)buprenorphine and dextromoramide both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine, dextromoramide. Other (see comment). Avoid or Use Alternate Drug. Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.diamorphineMonitor Closely (1)buprenorphine and diamorphine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine, diamorphine. Other (see comment). Avoid or Use Alternate Drug. Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.diazepamMonitor Closely (1)diazepam and buprenorphine both increase sedation. Use Caution/Monitor.diazepam intranasalSerious - Use Alternative (1)diazepam intranasal, buprenorphine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.difelikefalinMonitor Closely (1)difelikefalin and buprenorphine both increase sedation. Use Caution/Monitor.difenoxin hclMonitor Closely (1)buprenorphine and difenoxin hcl both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine, difenoxin hcl. Other (see comment). Avoid or Use Alternate Drug. Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.dimenhydrinateMonitor Closely (1)dimenhydrinate and buprenorphine both increase sedation. Use Caution/Monitor.diphenhydramineMonitor Closely (1)diphenhydramine and buprenorphine both increase sedation. Use Caution/Monitor.diphenoxylate hclMonitor Closely (1)buprenorphine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine, diphenoxylate hcl. Other (see comment). Avoid or Use Alternate Drug. Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.dipipanoneMonitor Closely (1)buprenorphine and dipipanone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine, dipipanone. Other (see comment). Avoid or Use Alternate Drug. Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.disopyramideSerious - Use Alternative (1)buprenorphine and disopyramide both increase QTc interval. Avoid or Use Alternate Drug.dofetilideSerious - Use Alternative (1)buprenorphine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.dolasetronSerious - Use Alternative (1)dolasetron and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.donepezilSerious - Use Alternative (1)donepezil and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.dopexamineMonitor Closely (1)buprenorphine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinMonitor Closely (1)buprenorphine and dosulepin both increase sedation. Use Caution/Monitor.doxepinMonitor Closely (1)buprenorphine and doxepin both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)doxepin and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.doxylamineMonitor Closely (1)doxylamine and buprenorphine both increase sedation. Use Caution/Monitor.dronedaroneContraindicated (1)buprenorphine and dronedarone both increase QTc interval. Contraindicated.droperidolMonitor Closely (1)buprenorphine and droperidol both increase sedation. Use Caution/Monitor.efavirenzMonitor Closely (1)efavirenz will decrease the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)efavirenz and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.elagolixMonitor Closely (1)elagolix will decrease the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eliglustatSerious - Use Alternative (1)buprenorphine and eliglustat both increase QTc interval. Avoid or Use Alternate Drug.eluxadolineSerious - Use Alternative (1)buprenorphine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions. .elvitegravirMinor (2)elvitegravir increases levels of buprenorphine by unknown mechanism. Minor/Significance Unknown. No dose adjustment of buprenorphine/naloxone is required upon coadministration with VITEKTA. Patients should be closely monitored for sedation and cognitive effects. elvitegravir decreases levels of naloxone by unknown mechanism. Minor/Significance Unknown. No dose adjustment of buprenorphine/naloxone is required upon coadministration with VITEKTA. Patients should be closely monitored for sedation and cognitive effects.elvitegravir/cobicistat/emtricitabine/tenofovir DFMonitor Closely (1)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.encorafenibMonitor Closely (1)encorafenib, buprenorphine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.Serious - Use Alternative (1)encorafenib and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.entrectinibSerious - Use Alternative (1)entrectinib and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.enzalutamideMonitor Closely (1)enzalutamide will decrease the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.eribulinSerious - Use Alternative (1)eribulin and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.erythromycin baseSerious - Use Alternative (1)buprenorphine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateSerious - Use Alternative (1)buprenorphine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateSerious - Use Alternative (1)buprenorphine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateSerious - Use Alternative (1)buprenorphine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.escitalopramSerious - Use Alternative (1)buprenorphine and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.esketamine intranasalMonitor Closely (1)esketamine intranasal, buprenorphine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateMonitor Closely (1)eslicarbazepine acetate will decrease the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.estazolamMonitor Closely (1)estazolam and buprenorphine both increase sedation. Use Caution/Monitor.ethanolMonitor Closely (1)buprenorphine and ethanol both increase sedation. Use Caution/Monitor.etomidateMonitor Closely (1)etomidate and buprenorphine both increase sedation. Use Caution/Monitor.etravirineMonitor Closely (1)etravirine will decrease the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.eucalyptusMinor (1)buprenorphine and eucalyptus both increase sedation. Minor/Significance Unknown.fedratinibMonitor Closely (1)fedratinib will increase the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fenfluramineMonitor Closely (1)buprenorphine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fentanylSerious - Use Alternative (2)fentanyl, buprenorphine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation. buprenorphine decreases effects of fentanyl by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration of mixed agonist/antagonist and partial agonist opioid analgesics may reduce fentanyl's analgesic effect and possibly precipitate withdrawal symptoms.fentanyl intranasalSerious - Use Alternative (2)fentanyl intranasal, buprenorphine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation. buprenorphine decreases effects of fentanyl intranasal by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration of mixed agonist/antagonist and partial agonist opioid analgesics may reduce fentanyl's analgesic effect and possibly precipitate withdrawal symptoms.fentanyl transdermalSerious - Use Alternative (2)fentanyl transdermal, buprenorphine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation. buprenorphine decreases effects of fentanyl transdermal by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration of mixed agonist/antagonist and partial agonist opioid analgesics may reduce fentanyl's analgesic effect and possibly precipitate withdrawal symptoms.fentanyl transmucosalSerious - Use Alternative (2)fentanyl transmucosal, buprenorphine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation. buprenorphine decreases effects of fentanyl transmucosal by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration of mixed agonist/antagonist and partial agonist opioid analgesics may reduce fentanyl's analgesic effect and possibly precipitate withdrawal symptoms.fexinidazoleSerious - Use Alternative (2)fexinidazole and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval. fexinidazole will increase the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fezolinetantContraindicated (1)buprenorphine will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsfingolimodSerious - Use Alternative (1)fingolimod and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.flecainideSerious - Use Alternative (1)buprenorphine and flecainide both increase QTc interval. Avoid or Use Alternate Drug.flibanserinMonitor Closely (1)buprenorphine and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.fluconazoleSerious - Use Alternative (1)buprenorphine and fluconazole both increase QTc interval. Contraindicated.fluoxetineSerious - Use Alternative (1)buprenorphine and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug.fluphenazineMonitor Closely (2)buprenorphine and fluphenazine both increase QTc interval. Use Caution/Monitor. buprenorphine and fluphenazine both increase sedation. Use Caution/Monitor.flurazepamMonitor Closely (1)flurazepam and buprenorphine both increase sedation. Use Caution/Monitor.fluvoxamineSerious - Use Alternative (1)buprenorphine and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.fosamprenavirMonitor Closely (1)fosamprenavir increases levels of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Potential for increased toxicity. .foscarnetSerious - Use Alternative (1)buprenorphine and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.fosphenytoinMonitor Closely (1)fosphenytoin will decrease the level or effect of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fostemsavirSerious - Use Alternative (1)buprenorphine and fostemsavir both increase QTc interval. Avoid or Use Alternate Drug.gabapentinMonitor Closely (1)gabapentin, buprenorphine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilMonitor Closely (1)gabapentin enacarbil, buprenorphine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.ganaxoloneMonitor Closely (1)buprenorphine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinSerious - Use Alternative (1)gemifloxacin and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.gemtuzumabSerious - Use Alternative (1)buprenorphine and gemtuzumab both increase QTc interval. Avoid or Use Alternate Drug.gilteritinibSerious - Use Alternative (1)gilteritinib and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.glasdegibSerious - Use Alternative (1)buprenorphine and glasdegib both increase QTc interval. Avoid or Use Alternate Drug.goserelinSerious - Use Alternative (1)buprenorphine and goserelin both increase QTc interval. Avoid or Use Alternate Drug.granisetronSerious - Use Alternative (1)granisetron and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.haloperidolMonitor Closely (1)buprenorphine and haloperidol both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.histrelinSerious - Use Alternative (1)buprenorphine and histrelin both increase QTc interval. Avoid or Use Alternate Drug.hydrocodoneSerious - Use Alternative (2)buprenorphine decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients. . hydrocodone, buprenorphine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.hydromorphoneMonitor Closely (1)buprenorphine and hydromorphone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)buprenorphine, hydromorphone. Other (see comment). Avoid or Use Alternate Drug. Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however,